Lv54
1020 积分 2024-11-29 加入
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies
19小时前
求助中
ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib
20小时前
已完结
Reframing the “Rescue Window”: From Physiological Upper Bounds to Actionable Thresholds
4天前
已完结
Ethics of Backfilling in Early-Phase Oncology Trials
11天前
已关闭
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial
12天前
已完结
Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody–drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study
12天前
已完结
Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody–drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study
12天前
已完结
Aneuploidy as a driver of human cancer
14天前
已完结
Tumor aneuploidy as a prognostic and predictive biomarker in immune checkpoint blockade
14天前
已完结
Targeting chromosomal instability and aneuploidy in cancer
14天前
已完结
皖公网安备34019202002308
